Veracyte, Inc.

NasdaqGM:VCYT Voorraadrapport

Marktkapitalisatie: US$2.5b

Veracyte Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Veracyte heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 43.6%, terwijl de Biotechs-industrie de winst zag groeien met 29.1% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 24%. Het rendement op eigen vermogen van Veracyte is 5.1%, en het heeft een nettomarge van 12.8%.

Belangrijke informatie

43.59%

Groei van de winst

45.84%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.04%
Inkomstengroei23.97%
Rendement op eigen vermogen5.07%
Nettomarge12.83%
Volgende winstupdate05 May 2026

Recente prestatie-updates uit het verleden

Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality

Mar 08
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality

Recent updates

VCYT: Revised Street Views Will Highlight Medium Term Revenue Guidance Story

Analysts now see a modestly lower upside for Veracyte, trimming the consensus price target by a few dollars to around the mid $30s. Recent research reflects a balance between reduced targets from several firms and a newer bullish initiation that emphasizes the company's longer term growth potential.

VCYT: Bullish Coverage And Margin Reset Will Strengthen Prostate Cancer Risk Position

Analysts now see Veracyte's fair value at $53, up from $51. This revision reflects updated assumptions around growth, profitability and valuation multiples informed by recent Street research, including both fresh coverage and revised price targets.

VCYT: Refreshed Models And 2026 Earnings Focus Will Support Long-Term Upside

Analysts have trimmed their average price target on Veracyte by about $1.60 to $47.00, reflecting refreshed models after recent results and updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research updates have focused on resetting expectations for Veracyte, with price targets adjusted downward and models refreshed after Q4 results.

VCYT: NCCN Risk Stratification Focus Will Support Future Cash Flow Repricing

Analysts have lowered their price target on Veracyte from $43.00 to about $38.59, citing updated assumptions for revenue growth, profit margins and future P/E following recent model revisions. This includes a reduced $37 target from one large Wall Street firm after Q4 results.

VCYT: 2026 Revenue Outlook And Higher Future P/E Will Lift Long-Term Upside

Analysts now set their Veracyte price target at $48.60, compared with $47.50 previously. This reflects updated views on revenue growth, profit margin assumptions and a higher future P/E multiple.

VCYT: Guideline Support And Margin Reset Will Strengthen Prostate Cancer Risk Role

Analysts have kept their $51.00 price target for Veracyte unchanged, citing updated assumptions that reflect slightly lower discount rates, modestly higher revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Veracyte issued earnings guidance for the fourth quarter of 2025, with expected total revenue between US$138 million and US$140 million, described as 16% to 18% growth for the period.

VCYT: NCCN Risk Stratification Focus Will Support Future Genomic Test Adoption

Narrative Update on Veracyte Analysts have kept their Veracyte fair value target steady at $43.00, citing updated NCCN prostate cancer guidelines that highlight Decipher’s role in risk stratification and support slightly adjusted assumptions for revenue growth, profit margins, and future P/E. Analyst Commentary Recent commentary points to the updated NCCN prostate cancer guidelines as a supportive data point for Veracyte’s Decipher test.

VCYT: NCCN Guideline Support Will Strengthen Prostate Cancer Risk Stratification Role

Analysts have lifted their price target on Veracyte from US$45.00 to US$51.00, citing updated NCCN guidelines that they view as incrementally favorable for the company’s Decipher prostate cancer test and its differentiation based on clinical evidence. Analyst Commentary Bullish analysts are framing the latest NCCN prostate cancer guideline update as a meaningful support for Veracyte’s Decipher test, especially around how it is positioned within risk stratification.

Veracyte: Profitable, De-Risked, And Ready To Run

Jan 16

VCYT: NCCN Guideline Support Will Shape Future Decipher Adoption And Competitive Risks

Analysts have lifted their price target on Veracyte from $28.40 to $43.00, citing updated NCCN prostate cancer guidelines that highlight the Decipher test in key risk stratification tables as support for a higher fair value assumption. Analyst Commentary Analysts point to the updated NCCN V3.2026 prostate cancer guidelines as a supportive data point for Veracyte, highlighting that Decipher is explicitly listed in the principles of risk stratification tables across several key prostate cancer settings.

VCYT: Updated NCCN Guidelines Will Support Gradual Risk Stratification Adoption

Analysts have modestly raised their price target on Veracyte to approximately $47.50 from about $46.30, citing slightly stronger long term growth and profitability expectations, as well as the incremental boost from updated NCCN guidelines that further differentiate the company’s Decipher prostate cancer test. Analyst Commentary Street research characterizes the NCCN guideline update as a net positive for Veracyte, with the Decipher prostate cancer test receiving prominent placement in risk stratification tables across multiple disease stages.

VCYT: New NCCN Guidelines Will Support Continued Market Differentiation

Analysts have raised their price target for Veracyte from $45.30 to $46.30, citing ongoing positive inclusion of the company’s Decipher test in updated clinical guidelines as a contributing factor. Analyst Commentary Analysts have examined the recent updates to the clinical guidelines and their implications for Veracyte’s Decipher test, highlighting both opportunities and potential challenges facing the company.

Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Nov 22
Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

VCYT: Expanded Prostate Cancer Guidelines Will Drive Demand Ahead

Veracyte's analyst price target has been raised from $41.10 to $45.30. Analysts cite stronger guidelines support, as well as improved revenue and profit growth expectations, as key drivers.

VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion

Narrative Update: Veracyte Analyst Price Target Revision Analysts have slightly reduced their price target for Veracyte, lowering it by $1 to $28. They cite solid recent performance but note that larger upside may be realized further into the future.

Advanced Genomic And Cancer Diagnostics Will Expand Global Health Markets

Analysts have modestly raised Veracyte’s fair value estimate to $41.22 from $39.75. They cite continued product momentum and optimistic guidance, despite lingering longer-term uncertainties.

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Aug 30
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business

Jun 15
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business

Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next

May 10
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next
User avatar

Decipher, Afirma And MRD Tests Will Broaden Future Markets

Veracyte’s Decipher test expansion and updated NCCN guidelines could drive significant revenue growth and market share in the prostate cancer segment.

Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality

Mar 08
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality

Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Mar 04
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price

Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price

Veracyte: Getting Frothy

Dec 11

Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Aug 18
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%

Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 09
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Jul 02
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price

Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Jun 06
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Opbrengsten en kosten

Hoe Veracyte geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:VCYT Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Dec 255176622671
30 Sep 254953021669
30 Jun 254792621271
31 Mar 254633320271
31 Dec 244462420469
30 Sep 24425-921269
30 Jun 24400-5420064
31 Mar 24375-6819561
31 Dec 23361-7419357
30 Sep 23343-5018650
30 Jun 23329-2918447
31 Mar 23311-3017453
31 Dec 22297-3717141
30 Sep 22284-4318740
30 Jun 22268-4917737
31 Mar 22251-4817130
31 Dec 21220-7618030
30 Sep 21187-7311924
30 Jun 21157-6310520
31 Mar 21123-658917
31 Dec 20117-358817
30 Sep 20113-348617
30 Jun 20113-318723
31 Mar 20122-228911
31 Dec 19120-138315
30 Sep 19116-877-1
30 Jun 19109-1273-8
31 Mar 19101-16670
31 Dec 1892-236515
30 Sep 1886-286315
30 Jun 1880-316115
31 Mar 1876-325914
31 Dec 1772-31550
30 Sep 1771-275314
30 Jun 1772-265215
31 Mar 1768-295216
31 Dec 1665-315215
30 Sep 1661-355315
30 Jun 1655-385215
31 Mar 1652-365013
31 Dec 1550-344813
30 Sep 1548-344813
30 Jun 1545-334711

Kwaliteitswinsten: VCYT heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (12.8%) VCYT } zijn hoger dan vorig jaar (5.4%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: VCYT is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 43.6% per jaar laten groeien.

Versnelling van de groei: De winstgroei van VCYT over het afgelopen jaar ( 174.9% ) overtreft het 5-jarig gemiddelde ( 43.6% per jaar).

Winst versus industrie: De winstgroei VCYT over het afgelopen jaar ( 174.9% ) overtrof de Biotechs -sector 50.1%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 5.1% ) van VCYT wordt als laag beschouwd.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/04/30 14:31
Aandelenkoers aan het einde van de dag2026/04/30 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Veracyte, Inc. wordt gevolgd door 24 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Paul KnightBrean Capital Historical (Janney Montgomery)
Sung Ji NamBTIG
Kyle MiksonCanaccord Genuity